These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15073741)

  • 1. The role of prescribing and referral bias in studies of the association between third generation oral contraceptives and increased risk of thromboembolism.
    Dunn N; White I; Freemantle S; Mann R
    Pharmacoepidemiol Drug Saf; 1998 Jan; 7(1):3-14. PubMed ID: 15073741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies.
    Rekers H; Norpoth T; Michaels MA
    Eur J Contracept Reprod Health Care; 1996; 1(1):21-30. PubMed ID: 9678134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives?
    Heinemann LA; Lewis MA; Assmann A; Gravens L; Guggenmoos-Holzmann I;
    Pharmacoepidemiol Drug Saf; 1996 Sep; 5(5):285-94. PubMed ID: 15073814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives and venous thromboembolism: consensus conference statement.
    Dialogues in Contraception Consensus Conference (1995: Chicago)
    Dialogues Contracept; 1996; ():1-8. PubMed ID: 12320455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy.
    Douketis JD; Ginsberg JS; Holbrook A; Crowther M; Duku EK; Burrows RF
    Arch Intern Med; 1997 Jul; 157(14):1522-30. PubMed ID: 9236553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users.
    Samuelsson E; Hägg S
    Acta Obstet Gynecol Scand; 2004 Jul; 83(7):674-81. PubMed ID: 15225194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of venous thromboembolic disease and OC use.
    Ory HW
    Dialogues Contracept; 1996; 5(1):4-7, 10. PubMed ID: 12347722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives.
    Alhenc-Gelas M; Plu-Bureau G; Guillonneau S; Kirzin JM; Aiach M; Ochat N; Scarabin PY
    J Thromb Haemost; 2004 Sep; 2(9):1594-600. PubMed ID: 15333036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The truth about oral contraceptives and venous thromboembolism.
    Shulman LP; Goldzieher JW
    J Reprod Med; 2003 Nov; 48(11 Suppl):930-8. PubMed ID: 14686030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolism during hormone therapy in Japanese women.
    Adachi T; Sakamoto S
    Semin Thromb Hemost; 2005 Jun; 31(3):272-80. PubMed ID: 16052396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial infarction and oral contraceptives, a retrospective case control study in England and Scotland ('MICA' Study).
    Dunn NR; Thorogood M; de Caestecker L; Mann RD
    Pharmacoepidemiol Drug Saf; 1997 Jul; 6(4):283-9. PubMed ID: 15073780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Limited changes in prescription of third-generation oral contraceptives after reports on elevated thrombosis risk and subsequent professional guidelines].
    Kersemakers PA; Kester AD; van der Weijden T
    Ned Tijdschr Geneeskd; 2000 Feb; 144(6):280-3. PubMed ID: 10687020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence exerted on drug prescribing by patients' attitudes and expectations and by doctors' perception of such expectations: a cohort and nested case-control study.
    Lado E; Vacariza M; Fernández-González C; Gestal-Otero JJ; Figueiras A
    J Eval Clin Pract; 2008 Jun; 14(3):453-9. PubMed ID: 18373568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.
    Sidney S; Petitti DB; Soff GA; Cundiff DL; Tolan KK; Quesenberry CP
    Contraception; 2004 Jul; 70(1):3-10. PubMed ID: 15208046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels.
    Legnani C; Cini M; Cosmi B; Poggi M; Boggian O; Palareti G
    Haematologica; 2004 Nov; 89(11):1347-51. PubMed ID: 15531457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives, hormone therapy and cardiovascular risk.
    Shapiro S
    Climacteric; 2008 Oct; 11(5):355-63. PubMed ID: 18781479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of selective prescribing in the increased risk of VTE associated with third-generation oral contraceptives.
    Jamin C; Benifla JL; Madelenat P
    Hum Reprod Update; 1999; 5(6):664-71. PubMed ID: 10652976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third- and second-generation oral contraceptives are associated with similar risk estimates for venous thromboembolism.
    Kaper RF; Norpoth T; Rekers H
    Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):1-15. PubMed ID: 10836658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific oral contraceptive use and venous thromboembolism resulting in hospital admission.
    Heuser P; Tonga K; Hopkins R; Henderson M; Weatherall M; Metcalfe S; Beasley R
    N Z Med J; 2004 Nov; 117(1206):U1176. PubMed ID: 15570345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.